Manufactured Object
UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity
UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact
FDA Reinstates Generic Drug Policy Group After April Firings
FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave
Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season
RSV; Infant immunization; Merck; Sanofi; Beyfortus; Enflonsia; FDA approval; supply chain; healthcare; AstraZeneca
Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site
Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact
Recent Developments in NLP and Generative AI for Life Sciences and Precision Medicine (2025)
NLP; Generative AI; life sciences; precision medicine; healthcare; large language models; multimodal AI; quality management; drug discovery; pharmacovigilance
Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey
Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo
FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote
SpyLock Technology: Recent News on Rapid Bispecific Antibody Screening
SpyLock technology; bispecific antibody screening; Bio-Rad Laboratories; Pioneer Antibody Discovery Platform; high-throughput screening; protein engineering; SpyTag/SpyCatcher; BiLockCatcher; drug development
Sanofi Commits $20 Billion to U.S. R&D and Manufacturing by 2030
Sanofi; $20 billion investment; U.S. manufacturing; R&D; job creation; drug launches; domestic partnerships
Sanofi Announces $20 Billion US Investment Over Five Years
Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships